Pacira Pharmaceuticals (PCRX) Given a $49.00 Price Target by Piper Jaffray Companies Analysts
Other equities research analysts have also issued reports about the stock. Canaccord Genuity lowered their price target on shares of Pacira Pharmaceuticals from $46.00 to $42.00 and set a hold rating for the company in a report on Tuesday, January 30th. Oppenheimer restated a hold rating on shares of Pacira Pharmaceuticals in a report on Thursday, November 9th. HC Wainwright restated a buy rating and issued a $52.00 price objective on shares of Pacira Pharmaceuticals in a report on Thursday, November 9th. JPMorgan Chase & Co. assumed coverage on shares of Pacira Pharmaceuticals in a report on Monday, December 18th. They issued a neutral rating and a $47.00 price objective for the company. Finally, Seaport Global Securities assumed coverage on shares of Pacira Pharmaceuticals in a report on Friday, January 19th. They issued a buy rating and a $50.00 price objective for the company. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the stock. The stock has an average rating of Hold and a consensus price target of $48.47.
Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) opened at $35.90 on Tuesday. Pacira Pharmaceuticals has a 1-year low of $29.81 and a 1-year high of $58.95. The company has a current ratio of 6.99, a quick ratio of 6.24 and a debt-to-equity ratio of 1.03. The company has a market cap of $1,460.00, a price-to-earnings ratio of -27.40 and a beta of 1.88.
A number of hedge funds have recently made changes to their positions in PCRX. Mesirow Financial Investment Management Equity Management purchased a new stake in Pacira Pharmaceuticals during the 3rd quarter valued at about $14,671,000. Stonepine Capital Management LLC purchased a new stake in Pacira Pharmaceuticals during the 3rd quarter valued at about $14,089,000. Epoch Investment Partners Inc. grew its position in Pacira Pharmaceuticals by 195.7% during the 3rd quarter. Epoch Investment Partners Inc. now owns 535,999 shares of the company’s stock valued at $20,127,000 after purchasing an additional 354,728 shares during the last quarter. Vanguard Group Inc. grew its position in Pacira Pharmaceuticals by 7.4% during the 2nd quarter. Vanguard Group Inc. now owns 3,072,074 shares of the company’s stock valued at $146,538,000 after purchasing an additional 211,982 shares during the last quarter. Finally, Renaissance Technologies LLC grew its position in Pacira Pharmaceuticals by 36.2% during the 4th quarter. Renaissance Technologies LLC now owns 509,900 shares of the company’s stock valued at $23,277,000 after purchasing an additional 135,400 shares during the last quarter.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.